Mohamad Morsey, Yuan-zheng Zhang, Denise Bartels-Morozov, Jason Erskine, and Ian Tarpey
- Intervet International B.V. [NL/NL]; Wim de Korverstraat 35, 5831 AN Boxmeer (NL)
- Intervet Inc., Summit, NJ (US)
The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
CovalX Technology Used
Mass spectroscopy was used to identify discontinuous epitopes that may be recognized by anti-canine PD-1. CovalX completed the epitope mapping of canine PD-1. Through this method, researchers were able to identify portions of epitopes that were recognized by mAbs. For example, mAb 3B6 recognizes part of an epitope that is located in the extracellular domain of canine-PD-1. Similarly, mAb 2G9 recognized part of an epitope within a different amino acid sequence (SEQ ID NO: 100). mAb 1E4 and mAb 1B5 each recognize other parts of an epitope within two different amino acid sequences known as SEQ ID NO: 101 and SEQ ID NO: 102. It was also found that caninized antibody 2G9 (R62, R69, R72, and R75) is recognizes the epitope on canine PD-1. R75 is considered to be an important amino acid residue by the researchers because it appeared in multiple epitopes of canine PD-1.